A large U.S. trial is putting risk-based breast cancer screening in the spotlight. The main takeaway for readers: it looks promising, but it has not replaced current screening guidance, and people should not change their schedule on their own.
A January 2026 federal update makes HPV-only screening the preferred option for many women 30 to 65 and adds self-collection as a choice.
Blood in the urine is not always cancer, but new research suggests delayed follow-up is common. Here’s what hematuria means and when prompt care matters.
An oral cancer screening during a dental visit is usually a simple look-and-feel exam of the mouth, throat area, and neck. It can help spot suspicious changes early, even though current evidence still does not prove that screening symptom-free adults lowers deaths.
A new March 3, 2026 modeling study suggests breast MRI may make the most sense for people with extremely dense breasts plus higher-than-average breast cancer risk. A dense-breast notice alone does not automatically mean you need an MRI.
New 2026 U.S. colorectal cancer statistics show a split trend: rates keep falling in many older adults but are rising in younger adults. Here is what that means for symptoms, screening at 45, family history, and why access still matters.
The FDA says promotional materials for Anktiva gave a misleading picture of what the bladder cancer drug can treat and how it is used. Here is what the drug is actually approved for, who it may fit, how it is given, and why the study behind the approval matters.
A new federal update says self-collected HPV testing should be offered as an option for average-risk women ages 30 to 65. Here’s what changed, what did not, and why many insurance plans may not have to cover the new option with no out-of-pocket costs until plan years that start in 2027.
Blood in the urine can be caused by many conditions, from infections to kidney stones. But painless bleeding is also the most common early sign of bladder cancer. Here’s what U.S. guidelines say about screening, who is at higher risk, and when to seek care.
The U.S. Preventive Services Task Force now recommends that most women start mammograms at age 40 instead of 50. Here’s what changed, what the evidence shows, and what it means for your health and insurance coverage.
If you are 50 to 80 years old and have a significant smoking history, you may qualify for annual low-dose CT lung cancer screening. Here’s what the current U.S. guidelines say about eligibility, benefits, risks, and insurance coverage.
The FDA continues to monitor rare cancers linked to breast implants, including BIA-ALCL and emerging reports of BIA-SCC. Here’s what patients need to know about symptoms, risk levels, informed consent, and insurance coverage.
As spring and summer approach, federal health agencies are reminding Americans that skin cancer is largely preventable. Here’s what the CDC, FDA, USPSTF, and National Cancer Institute say about UV exposure, sunscreen safety, and who should take extra precautions.
If you’re 50 to 80 and have a significant smoking history, you may qualify for annual low-dose CT lung cancer screening. Here’s what the evidence shows, who is eligible, what the trade-offs are, and how insurance coverage works in 2026.
Colorectal cancer screening now starts at age 45 for most adults. Here’s what current U.S. guidelines say, how stool tests compare with colonoscopy, what happens after a positive result, and what insurance and Medicare typically cover.
Blood in the urine—whether you can see it or not—should never be ignored. Here’s what hematuria can mean, when it may signal bladder cancer, how doctors evaluate it, and when to seek urgent care.
U.S. preventive care experts now recommend starting routine breast cancer screening at age 40 for women at average risk. Here’s what changed, who it affects, and how to decide what’s right for you.
Skin cancer remains the most common cancer in the United States. Here’s what current CDC, USPSTF, and FDA guidance says about sunscreen, UV exposure, and who should take extra precautions.
Cancer screening can lower the risk of dying from certain cancers—but only when it’s used at the right time and for the right people. Here’s what current U.S. recommendations say about breast, colorectal, lung, cervical, and prostate cancer screening, and how to decide what’s appropriate for you.
Blood in the urine can be alarming. Here’s what it may signal about bladder health, when to seek care, and what U.S. guidelines say about evaluation and cancer risk.
Cancer remains a leading cause of death in the United States, but prevention, screening, and treatment continue to improve. Here’s what current public health evidence shows—and what it means for individuals and families.
As spring and summer approach, public health agencies are reinforcing practical steps to prevent skin cancer. Here’s what the evidence shows about sunscreen, tanning, and early detection—and what it means for you and your family.
End of content
End of content
